| ANX7, a candidate tumor suppressor gene for prostate cancer. | prostate, |
| Haploinsufficiency of the tumor suppressor ANXA7 due to monosomy of chromosome 10 provides a clinically relevant mechanism to augment EGFR signaling in glioblastomas beyond that resulting from amplification of the EGFR gene. | glioblastoma, |
| a multi-hnRNP complex can be responsible for aberrant ANXA7 transcription and splicing, thereby affecting ANXA7 expression pattern and tumor suppressor function in prostate cancer. | prostate, |
| Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin | breast,prostate, |
| haploinsufficiency of Anx7 expression appears to drive disease progression to cancer because of genomic instability through a discrete signaling pathway involving other tumor suppressor genes, DNA-repair genes, and apoptosis-related genes | None |
| ANXA7 and p53 can distinctly regulate LOX transcription that is potentially relevant to the arachidonic acid -mediated cell growth control in tumor suppression. | None |
| Up-regulation of ANXA7-GTPase tumor suppressor reverses tumorigenesis. (Review) | None |
| Meanwhile, the key biomarkers of cell metastasis E-cadherin expression increased while MMP-9 decreased.we found that ANXA7 played its role via MAPK/ERK pathway. ANXA7 might involve in the development of hepatocellular carcinoma and act as an oncogene which might be a potential therapeutic target for treatment. | liver, |